In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients

Cancer Research

Volumn 69, Issue 7, 2009, Pages 2927-2934

  Schuurhuis, Danita H ^a   Verdijk, Pauline ^a   Schreibelt, Gerty ^a   Schreibelt, Erik H J G ^a   Scharenborg, Nicole ^a   De Boer, Annemiek ^a   Van de Rakt, Mandy W M M ^a   Kerkhoff, Marieke ^a   Gerritsen, Marie Jeanne P ^a   Eijckeler, Femke ^a   Bonenkamp, Johannes J ^a   Blokx, Willeke ^a   Van Krieken, J Han ^a   Boerman, Otto C ^a   Oyen, Wim J G ^a   Punt, Cornelis J A ^a   Figdor, Carl G ^a   Adema, Gosse J ^a   De Vries, I Jolanda M ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 100; INDIUM 111; MESSENGER RNA; MONOPHENOL MONOOXYGENASE; SUPERPARAMAGNETIC IRON OXIDE; TUMOR ANTIGEN; HLA A2 ANTIGEN; INDIUM;

ARTICLE; CANCER PREVENTION; CANCER SURGERY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DENDRITIC CELL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MELANOMA; MIGRATION; PRIORITY JOURNAL; VACCINATION; ADOPTIVE IMMUNOTHERAPY; BIOSYNTHESIS; ELECTROPORATION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; PATHOLOGY;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ELECTROPORATION; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDIUM RADIOISOTOPES; LYMPH NODES; LYMPHOCYTE ACTIVATION; MELANOMA; RNA, MESSENGER;

EID: 66149096672     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3920     Document Type: Article

References (38)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-252
2. Figdor CG1 de Vries IJ1 Lesterhuis WJ1 Mellef CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:475-480
3. de Vries IJ1 Bernsen MR1 Lesterhuis WJ1 et a!. Immunomonitoring tumor-specific T cells in delayed- type hypersensitivity skin biopsies after dendritic cell vaccination, correlates with clinical outcome. J Clin. Oncol 2005;23:5779-5787
4. Fay JW1 Palucka AK1 Paczesny S1 et al. Long-term, outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol Immunother 2006;55:1209-1218
5. Nestle 1'O1 Alijaglc S1 Gilliet M1 et a!. Vaccination of melanoma patients with peptide- or tumor lysate- pulsed dendritic cells. Nat Med 1998;4:328-332
6. Schuler-Thurner B1 Schultz ES1 Berger TG1 et al. Rapid induction of tumor-specific type 1 T helper cells in. metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte- derived dendritic cells. J Exp Med 2002;195:1279-1288
7. 111in-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccina- tion. Nucl Med Biol 2006;33:453-8.
8. Marshall JL, Hawkins MJ, Tsang KY, et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoem- bryonic antigen. J Clin Oncol 1999;17:332-337
9. Pécher G, Haring A, Kaiser L, Thiel E. Mucin gene (MUCl) transfected dendritic cells as vaccine: results of a phase I/II clinical trial. Cancer Immunol Immunother 2002;51:669-673
10. Bonehill A, Heirman C, Tuyaerts S, et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I, class II. molecules. J Immunol 2004;172:6649-6657
11. Nair SK, Morse M, Boczkowski D, et a!. Induction, of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002;235:540-549
12. Saeboe-Larssen S, Fossberg E, Gaudernack G. mRNA- based electrotransfectlon of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT). J Immunol Methods 2002:259:191-203.
13. Schaft N, Dorrie J, Thumann P, et al. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 2005;174:3087-3097
14. Su Z1 Dannull J, Yang BK. et al. Telomerase mRNA-transfected dendritic cells stimulate antigen- specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005:174: 3798-3807
15. Salcedo M, Bercovici N, Taylor R, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysáte. Cancer Immunol Immunother 2006;55:819-829
16. Hirschowitz EA, Foody T, Kryscio R, Dickson L, Sturgill J, Yannelli J. Autologous dendritic cell vaccines for non-small-cell lung cancer. J Clin Oncol 2004:22: 2808-2815
17. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005;28:496-504.
18. Avigan D1 Vaslr B1 Gong J1 et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004;10:4699-4708
19. Wei Y1 Sticca RP1 Holmes LM1 et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 2006:28:585-593
20. Grunebach F1 Müller MR, Brossait P. New developments In dendritic cell-based vaccinations: RNA translated into clinics. Cancer Immunol Immunother 2005:54: 5.17-25.
21. Ponsaerts P, Van Tendeloo VF, Bememan ZN. Cancer immunotherapy using RNA-loaded dendritic cells. Clin Exp Immunol 2003;134:378-384
22. Grunebach F, Müller MR, Nencioni A, Brossart P. Delivery of tumor-derived RNA for the induction, of cytotoxic T-lymphocytes. Gene Ther 2003:10:367-374
23. Tuyaerts S, Michiels A, Corthals J, et al. Induction of Influenza Matrix Protein 1. and MelanA-speciftc T lymphocytes in vitro using mRNA-electroporated dendritic cells. Cancer Gene Ther 2003;10:696-706.
24. Schuurhuis DH, Lesterhuis WJ, Kramer M, et al. Polyinoslnic polycytidylic acid prevents efficient antigen expression after mRNA electroporatlon of clinical grade dendritic cells. Cancer Immunol Immunother. Epub 2008 Nov 19.
25. Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo Veritas? Curr Opin Immunol 2005;17:170-174
26. Balen CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19: 3635-3648
27. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation, of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003;9:5091-5100
28. Berger TG, Strasser E, Smith R, et al. Efficient elutriation of monocytes within a closed, system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods 2005;298:61-72.
29. de Vries IJ, Lesterhuis WJ, Barentsz JO, et al. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 2005;23:1407-1413
30. de Vries IJ, Eggert AA Scharenborg NM, et al. Phenotypical and functional, characterization, of clinical. grade dendritic cells. J Immunother 2002;25:429-438
31. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3Al peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage TV melanoma. J Exp Med 1999;190:1669-1678
32. de Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003;63:12-17
33. Krooshoop DJ, Torensma R, van den Bosch GJ, et al. An automated multi well cell track system to study leu- kocyte migration. J Immunol Methods 2003;280:89-102.
34. Boullart AC, Aarntzen EH, Verdijk P, et al. Maturation, of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 Uganda combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother 2008;57:1589-1597
35. Verdijk P, Scheenen TW, Lesterhuis WJ, et al. Sensitivity of magnetic resonance imaging of dendritic cells for in vivo tracking of cellular cancer vaccines. Int J Cancer 2007;120:978-984
36. Michiels A1 Tuyaerts S, Bonehill A, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005;12:772-782
37. Verdijk P1 Aarntzen EMJG1 Lesterhuis WJ1 et al. Limited amounts of dendritic cells migrate into the T cell area of lymph nodes but have high immune activating potential, in. melanoma patients. Clin Cancer Res. In press 2009.
38. Vierboom. MP1 Zwaveling S1 Bos GMJ. et al. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 2000;60:5508-5513